Acute Kidney Injury and Heart Failure Risk with Hypoxia‐Inducible Factor–Prolyl Hydroxylase Inhibitors: A Network Meta‐Analysis
- 5 October 2026
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
Abstract
The aim of this systematic review and network meta‐analysis was to clarify the risk of acute kidney injury (AKI) and acute heart failure associated with hypoxia‐inducible factor–prolyl hydroxylase inhibitors (HIF‐PHIs) in patients with anemia of chronic kidney disease. The certainty of evidence for each outcome was assessed using the Confidence in Network Meta‐Analysis approach. The primary outcomes were AKI and acute heart failure, while the secondary outcome was any kidney injury. Thirty‐five studies, performed between 2009 and 2025, were included in the network meta‐analysis. HIF‐PHIs were associated with a higher risk of AKI compared with erythropoiesis‐stimulating agents (ESAs) (risk ratio [RR] 1.23, 95% confidence interval [CI] 1.02–1.47, moderate certainty) and placebo (RR 1.40, 95% CI 1.11–1.75, high certainty). HIF‐PHIs were also associated with an increased risk of any kidney injury compared with placebo (RR 1.13, 95% CI 1.01–1.26, moderate certainty). ESAs ranked lower in terms of acute heart failure risk than both HIF‐PHIs and placebo, although the differences were not statistically significant. Vadadustat (RR 0.30, 95% CI 0.12–0.74, moderate certainty) and ESAs (RR 0.40, 95% CI 0.17–0.94, high certainty) were associated with a lower risk of acute heart failure compared with placebo. In conclusion, HIF‐PHIs may be associated with an increased incidence of AKI compared with placebo and ESAs. In contrast, vadadustat and ESAs might be associated with a decreased incidence of acute heart failure compared with placebo. Further robust studies should be conducted to validate these findings.Keywords
This publication has 50 references indexed in Scilit:
- The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney diseaseKidney International, 2023
- Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase InhibitorsDrugs, 2022
- Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis PatientsJAMA Internal Medicine, 2022
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)Advances in Therapy, 2021
- Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKDKidney International Reports, 2021
- A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS StudyKidney International Reports, 2021
- Treatment of Anemia in Kidney Disease: Beyond ErythropoietinKidney International Reports, 2021
- Roxadustat for CKD-related Anemia in Non-dialysis PatientsKidney International Reports, 2021
- Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialAdvances in Therapy, 2019
- Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney diseaseKidney International, 2016